260 related articles for article (PubMed ID: 31093677)
41. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
Monfort SM; Pan X; Patrick R; Ramaswamy B; Wesolowski R; Naughton MJ; Loprinzi CL; Chaudhari AMW; Lustberg MB
Breast Cancer Res Treat; 2017 Jul; 164(1):69-77. PubMed ID: 28374323
[TBL] [Abstract][Full Text] [Related]
42. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
Greenlee H; Hershman DL; Shi Z; Kwan ML; Ergas IJ; Roh JM; Kushi LH
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27794123
[TBL] [Abstract][Full Text] [Related]
43. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Hershman DL; Unger JM; Crew KD; Till C; Greenlee H; Minasian LM; Moinpour CM; Lew DL; Fehrenbacher L; Wade JL; Wong SF; Fisch MJ; Lynn Henry N; Albain KS
J Natl Cancer Inst; 2018 Jun; 110(6):669-676. PubMed ID: 29361042
[TBL] [Abstract][Full Text] [Related]
44. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
45. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
47. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS).
Williams LA; Garcia-Gonzalez A; Mendoza TR; Haq S; Cleeland CS
Support Care Cancer; 2019 Mar; 27(3):1021-1028. PubMed ID: 30094731
[TBL] [Abstract][Full Text] [Related]
48. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
Rugo HS; Klein P; Melin SA; Hurvitz SA; Melisko ME; Moore A; Park G; Mitchel J; Bågeman E; D'Agostino RB; Ver Hoeve ES; Esserman L; Cigler T
JAMA; 2017 Feb; 317(6):606-614. PubMed ID: 28196257
[TBL] [Abstract][Full Text] [Related]
49. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
[TBL] [Abstract][Full Text] [Related]
50. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
Schneider BP; Li L; Radovich M; Shen F; Miller KD; Flockhart DA; Jiang G; Vance G; Gardner L; Vatta M; Bai S; Lai D; Koller D; Zhao F; O'Neill A; Smith ML; Railey E; White C; Partridge A; Sparano J; Davidson NE; Foroud T; Sledge GW
Clin Cancer Res; 2015 Nov; 21(22):5082-5091. PubMed ID: 26138065
[TBL] [Abstract][Full Text] [Related]
51. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies.
Nagano H; Sanai H; Muraoka M; Takagi K
Gynecol Oncol; 2012 Oct; 127(1):172-4. PubMed ID: 22750259
[TBL] [Abstract][Full Text] [Related]
53. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
55. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
56. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.
Fernandes R; Mazzarello S; Joy AA; Pond GR; Hilton J; Ibrahim MFK; Canil C; Ong M; Stober C; Vandermeer L; Hutton B; da Costa M; Damaraju S; Clemons M
Support Care Cancer; 2018 Sep; 26(9):3073-3081. PubMed ID: 29564623
[TBL] [Abstract][Full Text] [Related]
57. Electrophysiological and phenotypic profiles of taxane-induced neuropathy.
Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Boyle F; Goldstein D; Park SB
Clin Neurophysiol; 2020 Aug; 131(8):1979-1985. PubMed ID: 32291143
[TBL] [Abstract][Full Text] [Related]
58. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
59. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
[TBL] [Abstract][Full Text] [Related]
60. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
